Susana García-Recio

Susana García-Recio

UNVERIFIED PROFILE

Are you Susana García-Recio?   Register this Author

Register author
Susana García-Recio

Susana García-Recio

Publications by authors named "Susana García-Recio"

Are you Susana García-Recio?   Register this Author

17Publications

386Reads

24Profile Views

Corrigendum re: "TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer" [Eur Urol 2016;70:709-13].

Eur Urol 2017 08 1;72(2):e49. Epub 2017 Mar 1.

Translational Genomics and Targeted Therapeutics in Solid Tumours Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.02.027DOI Listing
August 2017

TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.

Eur Urol 2016 11 2;70(5):709-713. Epub 2016 Mar 2.

Translational Genomics and Targeted Therapeutics in Solid Tumours Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.02.034DOI Listing
November 2016

Biological and Pharmacological Aspects of the NK1-Receptor.

Biomed Res Int 2015 3;2015:495704. Epub 2015 Sep 3.

Laboratori d'Oncologia Molecular i Traslacional, Fundació Clínic per a la Recerca Biomèdica, 08036 Barcelona, Spain ; Departament de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/495704DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573218PMC
July 2016

The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation.

PLoS One 2015 26;10(6):e0129661. Epub 2015 Jun 26.

Department of Medical Oncology, Hospital Clínic, Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0129661PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482606PMC
April 2016

The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.

Int J Oncol 2014 Oct 28;45(4):1658-72. Epub 2014 Jul 28.

Institute of Neurosciences of Castilla y León (INCYL), Laboratory of Neuroanatomy of the Peptidergic Systems (Lab. 14), Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2014.2565DOI Listing
October 2014

Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.

Cancer Res 2013 Nov 12;73(21):6424-34. Epub 2013 Sep 12.

Authors' Affiliations: Department of Medical Oncology and Pathology, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Department of Medicine, University of Barcelona; Department of Cell Biology, Immunology, and Neurosciences, Medical School, University of Barcelona, Barcelona, Spain; Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea; Department of Genetics, Oslo University Hospital Radiumhospitalet, Norway; and Department of Medicine and Experimental Oncology, Torino University, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-4573DOI Listing
November 2013

Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.

J Cell Physiol 2012 Apr;227(4):1358-66

Department of Medical Oncology, Hospital Clínic, Medical School, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.22848DOI Listing
April 2012

Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.

Cancer Biol Ther 2011 Jan 1;11(1):4-13. Epub 2011 Jan 1.

Department of Medical Oncology, Universitat de Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.11.1.13672DOI Listing
January 2011

Tyrosine kinase receptor transactivation associated to G protein-coupled receptors.

Curr Drug Targets 2010 Sep;11(9):1169-80

Institut d'Investigacions Biomèdiques Agustí Pi y Sunyer, Laboratory of Molecular and Translational Oncology (ICMHO), University of Barcelona, Casanova 143, 08036 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945010792006807DOI Listing
September 2010

Tumor promoting effects of CD95 signaling in chemoresistant cells.

Mol Cancer 2010 Jun 23;9:161. Epub 2010 Jun 23.

Medical Oncology, Institut d'Investigacions Biomèdiques Agustí Pi y Sunyer (IDIBAPS), Institut Clínic de Malalties Hemato-Oncològiques (ICMHO), Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-9-161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906471PMC
June 2010

The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.

PLoS One 2009 6;4(3):e4728. Epub 2009 Mar 6.

Facultat de Medicina, Hospital Clínic, Institut d'Investigacions Biomèdiques Agustí Pi y Sunyer, Universitat de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004728PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648894PMC
May 2009